These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34150647)

  • 1. The Epithelial to Mesenchymal Transition Related Gene Calumenin Is an Adverse Prognostic Factor of Bladder Cancer Correlated With Tumor Microenvironment Remodeling, Gene Mutation, and Ferroptosis.
    Du Y; Miao W; Jiang X; Cao J; Wang B; Wang Y; Yu J; Wang X; Liu H
    Front Oncol; 2021; 11():683951. PubMed ID: 34150647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of CXCL12 expression reveals the significance of inflammatory fibroblasts in bladder cancer carcinogenesis and progression.
    Du Y; Cao J; Jiang X; Cai X; Wang B; Wang Y; Wang X; Xue B
    Cancer Cell Int; 2021 Nov; 21(1):613. PubMed ID: 34801033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
    Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
    Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer.
    Du Y; Liu Y; Cao J; Jiang X; Wang Y; Yu J; Wang B; Wang X; Xue B
    Front Immunol; 2023; 14():1113756. PubMed ID: 37153545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Validation of a Stromal EMT Related LncRNA Signature as a Potential Marker to Predict Bladder Cancer Outcome.
    Du Y; Wang B; Jiang X; Cao J; Yu J; Wang Y; Wang X; Liu H
    Front Oncol; 2021; 11():620674. PubMed ID: 33747932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic Changes in Myofibroblasts Affect the Carcinogenesis and Prognosis of Bladder Cancer Associated With Tumor Microenvironment Remodeling.
    Du Y; Sui Y; Cao J; Jiang X; Wang Y; Yu J; Wang B; Wang X; Xue B
    Front Cell Dev Biol; 2022; 10():833578. PubMed ID: 35309916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy.
    Wang T; Ding G; Wang X; Cui Y; Ma X; Ma J; Wu J
    Arch Med Res; 2024 Jan; 55(1):102927. PubMed ID: 38154234
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Tao Y; Li X; Zhang Y; He L; Lu Q; Wang Y; Pan L; Wang Z; Feng C; Xie Y; Lai Z; Li T; Tang Z; Wang Q; Wang X
    Front Genet; 2022; 13():1057302. PubMed ID: 36568387
    [No Abstract]   [Full Text] [Related]  

  • 10. An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer.
    Xiao Z; Cai Z; Deng D; Tong S; Zu X
    Front Immunol; 2022; 13():1000321. PubMed ID: 36211349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
    Qiu Y; Ye W; Wang C; Zang J
    Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
    Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calumenin contributes to epithelial-mesenchymal transition and predicts poor survival in glioma.
    Yang Y; Wang J; Xu S; Shi F; Shan A
    Transl Neurosci; 2021 Jan; 12(1):67-75. PubMed ID: 33623713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-associated fibroblasts and the related Runt-related transcription factor 2 (RUNX2) promote bladder cancer progression.
    Liu B; Pan S; Liu J; Kong C
    Gene; 2021 Apr; 775():145451. PubMed ID: 33482279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
    Caramelo B; Zagorac S; Corral S; Marqués M; Real FX
    Eur Urol Oncol; 2023 Aug; 6(4):366-375. PubMed ID: 36890105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
    Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
    Front Immunol; 2023; 14():955949. PubMed ID: 37006317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 19. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.